Background/Aims: Increased arterial stiffness is a well-known risk factor for cardiovascular disease. Cilostazol, a phosphodiesterase type 3 inhibitor, is a unique antiplatelet agent with vasodilatory and vasoprotective effects. Therefore, we hypothesized that cilostazol may affect arterial stiffness. Methods: We enrolled 161 patients (112 males; mean age, 63 years) who had undergone percutaneous coronary intervention (PCI) for ischemic heart disease. The brachial-ankle pulse wave velocity (baPWV), radial augmentation index (rAI), rAI adjusted for a heart rate of 75 beats/min (rAI75), central systolic blood pressure (cSBP), and central pulse pressure (cPP), were measured at baseline and at the 30-day follow-up. Parameter changes were compared between the cilostazol group (n = 51) and the control group (n = 110). Results: In the cilostazol group, the values for rAI, cSBP, and cPP all improved after 30 days, while the control group displayed no significant interval changes in these parameters. The changes in rAI75 and baPWV did not differ significantly between the two groups. The changes in rAI, cSBP, and cPP were related to brachial systolic blood pressure, brachial diastolic blood pressure, heart rate, and the use of cilostazol and beta-blockers. In a multivariate analysis, the use of cilostazol was identified an independent factor associated with changes in rAI, cSBP, and cPP.
Values are presented as mean ± SD. SBP, systolic blood pressure; CI, confidential interval; DBP, diastolic blood pressure; baPWV, brachial-ankle pulse wave velocity; rAI, radial augmentation index; rAI75, radial augmentation index for a heart rate of 75 bpm; PP, pulse pressure.
a Indicates significant changes (p < 0.05) during the 30-day follow-up in each group. Values are presented as mean ± SD unless otherwise indicated; Δ equates to the interval change of each value. PWVmean, the mean value of the right and left pulse wave velocity; rAI, radial augmentation index; rAI75, radial augmentation index for a heart rate of 75 bpm; SBP, systolic blood pressure; PP, pulse pressure; CCB, calcium channel blocker; RAASi, rennin-angiotensinaldosterone system inhibitors. 
